Caroline H. Siegel

Caroline H. Siegel

Auto-generated profile, based on publicly available information

Caroline H. Siegel

Division of Rheumatology, Hospital for Special Surgery, and the Department of Medicine, Weill Cornell Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
INIris Navarro‐Millán
Iris Navarro‐Millán
SSSebastian E. Sattui
Sebastian E. Sattui
ALAmit Lakhanpal
Amit Lakhanpal
DZDiane Zisa
Diane Zisa
CSCaroline H. Siegel
Caroline H. Siegel
MCMary K. Crow
Mary K. Crow
Objective: To report the clinical experience with anakinra in preventing mechanical ventilation in patients with coronavirus disease 2019 (COVID‐19), symptoms of cytokine storm syndrome, and acute hypoxemic respiratory failure.Methods: To be included in this retrospective case series, patients must have had severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2), fever, ferritin levels >1,000 ng/ml with 1 additional laboratory marker of hyperinflammation, and acute hypoxemic respiratory failure. Acute hypoxemic respiratory failure was defined as requiring 15 liters of supplemental oxygen via a nonrebreather mask combined with 6‐liter nasal cannula or use of ≥95% oxygen by high‐flow nasal cannula. We excluded patients in whom there was suspicion of bacterial infection or who were receiving immunosuppressants. Subcutaneous anakinra was initiated at 100 mg every 6 hours and gradually tapered off completely. The primary outcome was the prevention of mechanical ventilation.Results: Of the 14 patients who met the criteria, 11 patients received anakinra for a maximum of 19 days. Seven of the patients who started anakinra treatment ≤36 hours after onset of acute hypoxemic respiratory failure did not require mechanical ventilation, and all were discharged home. Four patients who started anakinra ≥4 days after onset of acute hypoxemic respiratory failure required mechanical ventilation. Of those, 3 patients were extubated (2 discharged home and 1 remained hospitalized), and 1 died. All 3 patients who met the criteria but did not receive anakinra required mechanical ventilation. Two patients were extubated (1 discharged home and 1 remained hospitalized), and 1 remained on mechanical ventilation.Conclusion: Our data suggest that anakinra could be beneficial in treating COVID‐19 patients with evidence of cytokine storm syndrome when initiated early after onset of acute hypoxemic respiratory failure. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in treating patients with COVID‐19 and symptoms of cytokine storm syndrome.

30 October 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MBMedha Barbhaiya
Medha Barbhaiya
JLJonah Levine
Jonah Levine
CSCaroline H. Siegel
Caroline H. Siegel
VBVivian P. Bykerk
Vivian P. Bykerk
DJDeanna Jannat-Khah
Deanna Jannat-Khah
LMLisa A. Mandl
Lisa A. Mandl

13 December 2022 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
BSBessie Stamm
Bessie Stamm
MBMedha Barbhaiya
Medha Barbhaiya
CSCaroline Siegel
Caroline Siegel
SLSarah Lieber
Sarah Lieber
MLMichael Lockshin
Michael Lockshin
LSLisa Sammaritano
Lisa Sammaritano
Fertility is often a concern for women with SLE. In addition to known indirect factors that influence the ability of a woman with SLE to become pregnant, such as cytotoxic agents, other medications, advanced age and psychosocial effects of the disease, direct disease-related factors are believed to influence fertility. These include diminished ovarian reserve, menstrual irregularities (a function of disease activity) and the presence of antiphospholipid antibodies. The question of whether SLE intrinsically affects fertility, however, remains unanswered. In this review, we address known factors affecting fertility, assess current data regarding a direct impact of SLE on fertility and evaluate potential disease-related risk factors. We focus primarily on studies measuring anti-Müllerian hormone and antral follicle count, the most widely measured markers of ovarian reserve. Our goal is to provide information to rheumatologists faced with counselling patients with SLE regarding their fertility, family planning and options for assisted reproductive technologies, which now include fertility preservation through oocyte cryopreservation.

1 October 2024 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
CSCaroline H. Siegel
Caroline H. Siegel
LSLisa R. Sammaritano
Lisa R. Sammaritano
Autoimmune rheumatic diseases (ARDs) often affect women during their reproductive years, and early studies of pregnancy in these patients reported high rates of adverse outcomes. Continuation or initiation of safe and effective medications in the preconception period is beneficial for maintaining or achieving disease quiescence throughout pregnancy thereby improving both maternal and pregnancy outcomes. The European Alliance of Associations for Rheumatology, the American College of Rheumatology, and the British Society for Rheumatology have published recommendations and guidelines regarding management of ARDs during pregnancy. The American College of Obstetricians and Gynecologists and the American Gastroenterological Association have also provided guidance statements with relevant recommendations. This review provides an overview of available recommendations for medication use in ARD pregnancy, with discussion of safety considerations for maternal and fetal well-being. Medications considered compatible with pregnancy include hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, tacrolimus, and TNF inhibitors. Methotrexate, mycophenolate, leflunomide, and cyclophosphamide should be avoided before and during pregnancy. Other medications, most of them newer, are largely discouraged for use in pregnancy due to inadequate data or concerns for neonatal immunosuppression, including non-TNF biologics and small molecule therapies. Further investigation is needed regarding effects of non-TNF biologics, biosimilars, and small molecules in pregnancy. Important efforts for the future will include improved methodologies to gather critical safety data, with consideration of inclusion of pregnant women in clinical trials, a complex and controversial issue. Long-term information on outcomes in offspring of treated women is lacking for many of these medications.

4 March 2021 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
CSCaroline H. Siegel
Caroline H. Siegel
JKJuliette Lcsw Kleinman
Juliette Lcsw Kleinman
MBMedha Barbhaiya
Medha Barbhaiya
ESEcem Sevim
Ecem Sevim
JVJoAnn BA Vega
JoAnn BA Vega
LSLisa R. Sammaritano
Lisa R. Sammaritano
Background/Objective: Despite increased awareness of the diagnosis and treatment of undifferentiated connective tissue disease (UCTD), there is little research on related psychosocial factors. This cross-sectional study qualitatively assesses the psychosocial impact of UCTD on patient health and well-being. Methods: We identified 20 adult patients with UCTD enrolled in the UCTD and Overlap Registry at our tertiary care level hospital. A licensed clinical social worker administered a 30-minute semistructured interview by telephone. The standardized questionnaire consisted of 14 open-ended questions on UCTD. A team of physicians, research coordinators, and a social worker used grounded theory to analyze the qualitative data and identify themes. Results: Among 14/20 study participants (100% female; mean age, 53.6 ± 13.2 years [range, 27–74 years]), all had at least an associate's/bachelor's degree; 9 (64%) were White. The mean disease duration was 14.5 ± 13.5 years (range, 0.5–44 years). Nine study participants (64%) were engaged in counseling or mindfulness training. Ten specific psychosocial themes and categories emerged, including the need for professional guidance and peer and family support to increase awareness, reduce isolation, and promote self-efficacy. Conclusions: Emerging themes from semistructured interviews of women with UCTD at a major academic center suggest the need for psychosocial interventions (e.g., patient support groups, educational materials, peer counselors) to help UCTD patients manage and cope with their illness. Future studies evaluating the psychosocial impact of UCTD diagnosis on diverse cohorts are needed.

23 January 2025 in ACR Open Rheumatology
Verified
Journal Article
Open access
CSCaroline H. Siegel
Caroline H. Siegel
DJDeanna Jannat‐Khah
Deanna Jannat‐Khah
AMAvi L. Mikhaylov
Avi L. Mikhaylov
PFPatrick Fritz
Patrick Fritz
EAErika L. Abramson
Erika L. Abramson
NPNancy Pan
Nancy Pan
Objective: This quality improvement initiative aimed to increase the rate of provider screening and documentation of contraception use for reproductive‐aged women seen in an academic rheumatology fellows’ clinic to >50% by 24 weeks, with sustained improvement at one year.Methods: With a multidisciplinary team, we devised and implemented six interventional cycles over 24 weeks informed by key stakeholder survey responses. The primary outcome measure was the percentage of eligible visits with contraception information documented in the structured electronic health record field. The smoking status documentation rate was tracked as a balancing measure, and the percentage of contraception documenters who were non–medical doctor (MD) clinical staff, the target group for the intervention, was tracked as a process measure. Outcome, process, and balancing measures were assessed every two weeks over one year.Results: Over 24 weeks, the rate of contraception documentation increased from 11% to 54% (median 30%), and the median smoking status documentation rate was 88% (68%–97% range); the median rate of non‐MD clinical staff documenters was 92% (70%–100% range). Interventions included an introductory educational session with documentation instruction and scripts to guide screening, email reminders from nursing leadership, and interim educational sessions. At one year, the contraception documentation rate was sustained at 50%.Conclusion: A multicycle educational intervention led to an increase in the contraception documentation rate from 11% to 54% for reproductive‐aged women seen in an academic rheumatology fellows’ clinic over 24 weeks, with sustained improvement at one year. Future interventions will focus on increasing contraception counseling and referrals for patients in rheumatology clinics who were high risk.